Table 4.
Associations between intellectual disability and outcomes among those diagnosed with bowel cancer
| No ID | ID | RR (95% CI) | |
|---|---|---|---|
| Route to diagnosis | N / total diagnosesa | N / total diagnosesa | |
| Screening | 10 / 349 (2.9%) | 580 / 5571 (10.4%) | 0.27 (0.14-0.50) |
| Urgent suspected cancer referral | 72 / 349 (20.6%) | 1896 / 5571 (34.0%) | 0.62 (0.50-0.76) |
| Emergency presentation | 136 / 349 (39.0%) | 1240 / 5571 (22.3%) | 1.76 (1.52-2.02) |
| Diagnosis recorded on date of death | N / total diagnoses | N / total diagnoses | |
| 60 / 6085 (1.0%) | 16 / 381 (4.2%) | 5.08 (2.92-8.84) | |
| Curative surgery within 6 months | N / total with non-metastatic diseaseb | N / total with non-metastatic diseaseb | |
| 1813 / 2218 (81.7%) | 95 / 118 (80.5%) | 0.98 (0.79-1.19) | |
| SACT within 6 months for metastatic disease | N / total with metastatic diseaseb,c | N / total with metastatic diseaseb,c | |
| 241 / 476 (50.6%) | <5 / 34 | 0.15 (0.05-0.46) | |
| Stage at diagnosis | N | N | |
| Stage I | 736 (12.1%) | 36 (9.4%) | |
| Stage II | 979 (16.1%) | 53 (13.9%) | |
| Stage III | 1179 (19.4%) | 69 (18.1%) | |
| Stage IV | 1178 (19.4%) | 89 (23.4%) | 1.25 (1.01-1.56)d |
| Unknown | 2013 (33.1%) | 134 (35.2%) | 1.08 (0.91-1.29)e |
ID intellectual disability, FIT faecal immunochemical test, FOB faecal occult blood test, RR risk ratio, CI confidence interval, SACT systemic anticancer therapy
aWith recorded route to diagnosis
bWith required follow-up
cFrom 2014 due to availability of SACT data
dStage 4 vs. stages 1–3
eKnown stage vs. unknown stage